A Survey of Medical Oncologist’s Opinions and Perceptions Regarding the Management of Dermatologic Toxicities among mCRC Patients Treated with Vectibix (20160258)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/21200
• EU PAS number:
  EUPAS18060
• Study ID:
  21200
• Official title and acronym:
  A Survey of Medical Oncologist’s Opinions and Perceptions Regarding the Management of Dermatologic Toxicities among mCRC Patients Treated with Vectibix (20160258)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  The study population consisted of practicing oncologists in the United States who treat patients with mCRC. Oncologists were recruited from a national database through a third party panel provider, M3 Global Research®. M3 Global Research® has access to over two million physicians and one million health care professionals globally for participation in both qualitative and quantitative studies. The oncologists were sampled at random and then stratified by size of institution, type of institution (academic cancer centers and community hospitals) and region within the United States to assess the following objectives: • Describe oncologist’s opinions regarding the management of dermatologic toxicities, including opinions regarding the timing of rash management in relation to the initiation of treatment with Vectibix and the manner in which the rash is managed. • Describe oncologist’s perceptions about the manner in which they preparing their patients for the possibility of developing dermatologic toxicities.
• Study status:
  Finalised

Research institutions and networks

Institutions

Amgen

United States

Study timelines

Date when funding contract was signed

Planned: 15/07/2016

Actual: 15/07/2016

Study start date

Planned: 09/09/2016

Actual: 09/09/2016

Data analysis start date

Planned: 24/09/2016

Actual: 18/10/2016

Date of final study report

Planned: 18/10/2016

Actual: 18/10/2016

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Amgen

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable